Metal Ion (Fe2+ and Co2+) Induced Morphological Transformation of Self-Aggregates of Cholesterol-Tethered Bipyridine Amphiphiles: Selective Cancer Cell Killing by Pro-Drug Activation

2019 ◽  
Vol 2 (9) ◽  
pp. 3737-3747 ◽  
Author(s):  
Soumik Dinda ◽  
Prasanta Kumar Das
Keyword(s):  
Cancer Cell ◽  
Metal Ion ◽  
Cell Killing ◽  
Morphological Transformation ◽  
Drug Activation

Combination of Oncolytic Adenoviral Therapy with Chemotherapy for Enhanced Breast Cancer Cell Killing – Virotherapy in combination with chemotherapy

2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
J Jung ◽  
A Nedeljkovic-Kurepa ◽  
B Glover ◽  
DT Curiel ◽  
RK Schmutzler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cell Killing

scholarly journals Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

Viruses ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1420
Author(s):  
Dirk M. Nettelbeck ◽  
Mathias F. Leber ◽  
Jennifer Altomonte ◽  
Assia Angelova ◽  
Julia Beil ◽  
...  
Keyword(s):  
Cancer Cell ◽  
Targeted Delivery ◽  
Viral Vector ◽  
Checkpoint Inhibitors ◽  
Therapeutic Proteins ◽  
Cancer Therapeutics ◽  
Cell Killing ◽  
Oncolytic Viruses ◽  
Preclinical Research ◽  
Research Activities

Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that cover endeavors from screening and engineering viruses as oncolytic cancer therapeutics to their clinical translation in investigator-initiated and sponsored multi-center trials. Preclinical research explores multiple viral platforms, including new isolates, serotypes, or fitness mutants, and pursues unique approaches to engineer them towards increased safety, shielded or targeted delivery, selective or enhanced replication, improved immune activation, delivery of therapeutic proteins or RNA, and redirecting antiviral immunity for cancer cell killing. Moreover, several oncolytic virus-based combination therapies are under investigation. Clinical trials in Germany explore the safety and potency of virotherapeutics based on parvo-, vaccinia, herpes, measles, reo-, adeno-, vesicular stomatitis, and coxsackie viruses, including viruses encoding therapeutic proteins or combinations with immune checkpoint inhibitors. These research advances represent exciting vantage points for future endeavors of the German virotherapy community collectively aimed at the implementation of effective virotherapeutics in clinical oncology.

Transition-metal ion-mediated morphological transformation of pyridine-based peptide nanostructures

2021 ◽  
Vol 45 (1) ◽  
pp. 153-161
Author(s):  
Narendra Singh ◽  
Ramesh Singh ◽  
Swati Sharma ◽  
Khushboo Kesharwani ◽  
Khashti Ballabh Joshi ◽  
...  
Keyword(s):  
Transition Metal ◽  
Metal Ion ◽  
Chemical Structure ◽  
Morphological Transformation ◽  
Transition Metal Ion

Pyridine-mediated constitutionally isomeric artificial metallopeptides possess remarkable advantages over the natural counterparts mainly due to their tailor-made chemical structure.

600 In vitro anticancer and immunomodulatory activities of NBT-167, a dimer of resveratrol

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A635-A635
Author(s):  
Jeffrey Zhang ◽  
Everett Henry ◽  
L Harris Zhang ◽  
Wanying Zhang
Keyword(s):  
T Cells ◽  
T Cell ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Immune Cells ◽  
Cell Killing ◽  
Gamma Delta T Cells ◽  
Gamma Delta ◽  
Raw264.7 Macrophages

BackgroundResveratrol (3,4’,5-trihydroxystilbene), a stilbenoid isolated from many species of plants, is widely known for its antioxidative, anti-inflammatory, immunomodulatory and anticancer activities. Recently, novel resveratrol oligomers have been isolated from various plants; their diverse structures are characterized by the polymerization of two or more resveratrol units. Little is known regarding the anticancer and immunomodulating activities of these oligomers. In this study, we designed in vitro models to compare resveratrol side by side with its natural dimer NBT-167 for their anticancer and immunological activities.MethodsWe isolated resveratrol and its dimer (NBT-167) from plants. The potency of the compounds was compared side by side using cancer cell survival assays and immunological assays with various types of human cells including cancer cell lines, PBMCs and enriched NK, gamma delta T cells, THP-1 monocytic cells, HL-60 promyelocytic leukemia cells as well as mouse RAW264.7 macrophages.ResultsNBT-167 was found to be more potent than resveratrol in inhibiting growth of various cancer cells and modulation of cytokine production from anti-IgM, LPS, PHA or SEB stimulated PBMC. Both compounds similarly enhanced IL-2 stimulated NK and gamma delta T cell killing activity against K562 cells and modulated nitric oxide production from LPS/IFN-g induced RAW264.7 macrophages and phagocytotic activity of HL-60 cells. NBT-167 was slightly more potently than resveratrol in inhibiting chemotaxis of HL-60 cells and blocking cell cycle of THP-1 and HL-60 cells at G1/S transition. In addition, NBT-167, but not resveratrol, could increase IL-2 production and T cell proliferation stimulated with anti-CD3 and anti-CD28 and synergize with anti-PD-1 antibody to increase IL-2 and IFN-gamma production in co-culture of allotypic T cells and dendric cells (MLR).ConclusionsOur data showed that NBT-167, a dimer of resveratrol, had anticancer and immunomodulatory activities such as modulation of expression of cytokines in immune cells and induction of cancer cell-killing activities of NK and gamma delta T cells. Generally, NBT-167 appeared to have higher activities than resveratrol in modulating immune cells and inhibiting cancer cells. NBT-167 could be a promising cancer immunotherapeutic agent targeting both cancer cells and immune cells.

scholarly journals Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing

2015 ◽  
Vol 151 (3) ◽  
pp. 529-539 ◽  
Author(s):  
Yong Wu ◽  
Marianna Sarkissyan ◽  
Eva Mcghee ◽  
Sangkyu Lee ◽  
Jaydutt V. Vadgama
Keyword(s):  
Breast Cancer ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cell Killing ◽  
Inhibition Of Glycolysis

Pre-clinical models of cellular therapy combined with cytokines demonstrate in vitro and in vivo ovarian cancer cell killing

2012 ◽  
Vol 125 ◽  
pp. S45
Author(s):  
S. Ingersoll ◽  
S. Ahmad ◽  
G. Stoltzfus ◽  
M. Merchant ◽  
A. Ahmed ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cell ◽  
Cellular Therapy ◽  
Ovarian Cancer Cell ◽  
Cell Killing ◽  
Clinical Models

Cytotoxicity and Antibacterial Studies of Newly Synthesized Novel Heterocylcic Pyridine Derivative and its Metal Complexes

2021 ◽  
Vol 6 (4) ◽  
pp. 243-249
Author(s):  
B.R. Chaitanya Kumar ◽  
K. Sudhakar Babu ◽  
J. Latha
Keyword(s):  
Metal Complexes ◽  
Cell Lines ◽  
Cancer Cell ◽  
Metal Ion ◽  
Analytical Data ◽  
Cancer Cell Lines ◽  
Diffusion Method ◽  
Pyridine Derivative ◽  
Bacterial Strains ◽  
Physico Chemical

A pyridine derivative 2-((E)-1-(2-hydrazinyl-4-methyl-6-phenyl-pyridine-3-carboyl)ethyl)pyridine-4- carbonitrile (CPHPC) ligand and its 3d-metal(II) complexes has been synthesized (where [M = Co(II), Ni(II) and Cu(II)]. The physico-chemical, analytical data, UV-Vis, FT-IR, 1H NMR and ESR spectrum methods were used to characterize all of the synthesized complexes. Spectral investigations of metal(II) complexes revealed that the metal ion is surrounded by an octahedral geometry. Low conductance values indicated that the metal(II) complexes behave as non-electrolyte. The cytotoxic activity on lung cancer cell lines and hepatic cancer cell lines A549 and HepG2, respectively, with the ligand and their metal complexes were tested with MTT assay. The ligand and its metal complexes were tested for diverse harmful bacterial strains using the agar well diffusion method on Gram-negative bacteria such as Pseudomonas desmolyticum, Escherichia coli and Klebsiella aerogenes, as well as Gram-positive bacteria Staphylococcus aureus.

Development of a novel potency assay to quantify immune cell-mediated cancer cell killing

Cytotherapy ◽  
2017 ◽  
Vol 19 (5) ◽  
pp. S41
Author(s):  
A. Oumie ◽  
A. Chan ◽  
M. Baradez ◽  
D. Marshall
Keyword(s):  
Cancer Cell ◽  
Immune Cell ◽  
Cell Killing ◽  
Potency Assay
Sign in / Sign up

Export Citation Format

Share Document